News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tripos (TRPS) Extends Its COMT Inhibitor Program With CeNeS Pharmaceuticals PLC (CEN.L)


9/12/2006 11:56:12 AM

ST. LOUIS & CAMBRIDGE, England--(BUSINESS WIRE)--Sept. 12, 2006--Tripos, Inc. (Nasdaq:TRPS), a leading provider of drug discovery chemistry and informatics products and services, and CeNeS Pharmaceuticals plc (AIM:CEN), a central nervous system (CNS)-focused biopharmaceutical company, announced today that they have extended their research agreement to develop catechol-O-methyltransferase (COMT) inhibitors to treat Parkinson's disease. Terms of the agreement were not disclosed.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES